Pair Name	Cryptotanshinone, Arsenic Trioxid
Phytochemical	Cryptotanshinone
Drug	Arsenic Trioxid
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	The therapeutic potential of ACCS as a candidate option for anticancer drugs in restoring the balance of immunity and metabolism deserves further investigation.

Pair Name	Rhizoma Paridis saponins, Sorafenib
Phytochemical	Rhizoma Paridis saponins
Drug	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	All of that provided possibility to overcome the intolerance of sorafenib by drug compatibility through protection against mitochondria damage, inhibition of anaerobic glycolysis and suppression of lipid synthesis based on PI3K/Akt/mTOR pathway.

Pair Name	Ursolic acid, Doxorubicin
Phytochemical	Ursolic acid
Drug	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	Ursolic acid augments the chemosensitivity of drug-resistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction

Pair Name	Vitamin C, Erastin
Phytochemical	Vitamin C
Drug	Erastin
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Regulate Info	Up-regulation	Solute carrier family 2		Expression
Result	The combination of erastin and vitamin C exerts a synergistic effect of classical and nonclassical modes to induce ferroptosis in PC cells, which may provide a promising therapeutic strategy for PC.

Pair Name	Vitamin C, Oxaliplatin
Phytochemical	Vitamin C
Drug	Oxaliplatin
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	The current study showed that GLUT1 expression was inversely correlated with sensitivity of gastric cancer cells to pharmacological ascorbate and suggested that GLUT1 expression in gastric cancer may serve as a marker for sensitivity to pharmacological ascorbate.

Pair Name	Saikosaponin D, Gefitinib
Phytochemical	Saikosaponin D
Drug	Gefitinib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	Saikosaponin D enhances the antitumor effect of gemcitabine by controlling glucose metabolism and drug efflux by inhibiting the ADRB2 signaling. Therefore, the combination of saikosaponin D and gemcitabine may be a potential therapeutic strategy for the treatment of iCCA.

Pair Name	Saikosaponin D, Gefitinib
Phytochemical	Saikosaponin D
Drug	Gefitinib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	Saikosaponin D enhances the antitumor effect of gemcitabine by controlling glucose metabolism and drug efflux by inhibiting the ADRB2 signaling. Therefore, the combination of saikosaponin D and gemcitabine may be a potential therapeutic strategy for the treatment of iCCA.

Pair Name	Shikonin, Gemcitabine
Phytochemical	Shikonin
Drug	Gemcitabine
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Regulate Info	Down-regulation	Solute carrier family 2		Expression
Result	These results indicate that shikonin reduced MCT4 expression and activation, resulting in inhibition of aerobic glycolysis in CAFs and overcoming CAF-induced gemcitabine resistance in PC. Shikonin is a promising chemosensitizing phytochemical agent when used in combination with gemcitabine for PC treatment. The results suggest that disrupting the metabolic coupling between cancer cells and stromal cells might provide an attractive strategy for improving gemcitabine efficacy.